Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CT-P17 Auto-injector vs Pre-filled Syringe in Healthy Subjects
NCT04295356Phase 1Completed
- Sponsor
- Celltrion
- Start
- Jun 2019
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of adalimumab in rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA) and 6 more (2 arms), sponsored by Celltrion. Primary endpoints: Peak Plasma Concentration at Day 71, Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity and 1 more. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)juvenile idiopathic arthritis (JIA)psoriatic arthritis (PsA)ankylosing spondylitis (AS)Crohn's disease
Beyond the preview
Go deeper on NCT04295356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04295356.